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Abstract
A novel design of gold-coated iron oxide nanoparticles was fabricated as a potential 1
delivery system to improve the efficiency and stability of d, l-sulforaphane as an 2
anticancer drug. To this purpose, the surface of gold-coated iron oxide nanoparticles 3
was modified for sulforaphane delivery via furnishing its surface with thiolated 4
polyethylene glycol-folic acid and thiolated polyethylene glycol-FITC. The synthesized 5
nanoparticles were characterized by different techniques such as FTIR, energy dispersive 6
X-ray spectroscopy, UV-visible spectroscopy, scanning and transmission electron 7
microscopy. The average diameters of the synthesized nanoparticles before and after 8
sulforaphane loading were obtained ∼ 33 nm and ∼ 38 nm, respectively, when ∼ 9
2.8 mmol/g of sulforaphane was loaded. The result of cell viability assay which was 10
confirmed by apoptosis assay on the human breast cancer cells (MCF-7 line) as a model 11
of in vitro-cancerous cells, proved that the bare nanoparticles showed little inherent 12
cytotoxicity, whereas the sulforaphane-loaded nanoparticles were cytotoxic. The 13
expression rate of the anti-apoptotic genes (bcl-2 and bcl-xL), and the pro-apoptotic 14
genes (bax and bak) were quantified, and it was found that the expression rate of bcl-2 15
and bcl-xL genes significantly were decreased when MCF-7 cells were incubated by 16
sulforaphane-loaded nanoparticles. The sulforaphane-loaded into the designed 17
gold-coated iron oxide nanoparticles, acceptably induced apoptosis in MCF-7 cells. 18
Introduction 19
Many studies confirmed that sulforaphane (SF) which was found in broccoli, cauliflower, 20
kale and other cruciferous vegetables, and chemically was named 21
1-isothiocyanato-4-(methylsulfinyl)-butane, acts as an efficient incidence reducer in 22
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various types of tumors [1–3]. It has been revealed that SF has a promising and 23
powerful anti-carcinogen effect in various cancers such as prostate, breast, osteosarcoma, 24
bladder, pancreatic, hepatic, and melanoma [4–7]. SF as an antitumor agent acts via 25
different mechanisms such as inhibiting angiogenesis and metastasis, inducing apoptosis, 26
and reducing inflammation [8–11]. Despite the mentioned benefits of SF as an 27
antitumor drug, its instability and sensitivity to oxygen, heat, and alkaline conditions, 28
limits the usage of SF in pharmaceutical industries [12,13]. 29
In recent decades, nanoparticles (NPs) have opened bright horizons to develop new 30
drug delivery systems (DDSs) due to their potential-biomedical-applications [14–17]. 31
One type of nanoparticle is the magnetic NP which has various biomedical applications 32
such as magnetic separator, magnetic-resonance-imaging contrast agent, and targeted 33
drug deliver for cancer therapy [18–24]. The targeted drug delivery using magnetic NPs 34
is a very useful technique to improve the performance of cancer treatment due to the 35
several advantageous including the superparamagnetic property, inertness, ease of 36
detection in the human body and high biocompatibility [25–27]. However, the naked 37
iron oxide NPs are easily oxidized in air (especially magnetite). Therefore, in order to 38
keep the stability of magnetic iron oxide NPs, it is important to develop protection 39
strategies. These strategies comprise grafting or coating with polymers, biomolecules, 40
organic molecules (small organic molecules or surfactants), or coating with an inorganic 41
layer, such as silica, hydroxyapatite, metal, nonmetal elementary substance, metal oxide, 42
or metal sulfide. Practically, it is worth to mention that in many cases the protecting 43
shells not only stabilize the magnetic iron oxide NPs, but also will be used for further 44
functionalization [28–30]. Regarding the mentioned points, Fe3O4@Au would be a good 45
candidate as a drug delivery carrier. 46
By focusing on the medicinal properties of SF and in continuation of our 47
experiences [31,32], the aim of this study is to design and synthesis a nano-DDS based 48
on [Fe3O4@Au] NPs to enhance the absorption and therapeutic level of SF as a 49
promising antitumor drug. In order to pursue the drug delivery and absorption, FITC 50
via thiolated polyethylene glycol was coated on the surface of gold-iron oxide core shell 51
nanoparticle. Hence, we enabled to evaluate the efficiency of SF-delivery with 52
fluorescence microscopy. 53
Since folate is essential for DNA synthesis and cell division and folic acid is an 54
important vitamin required for healthy functioning of all cells, the folate in the cancer 55
cells (divide more rapidly) is much more than the average amounts of folate in the 56
normal cells. Therefore, folate receptors are often over expressed on the surface of many 57
human cancerous cells including endometrial, renal, colon, and breast [33–35]. Thus, 58
folic acid, that is a non-immunogenic ligand, has emerged as an attractive specific 59
targeting molecule for anticancer drug delivery. Therefore, we propose a possible folic 60
acid conjugated Fe3O4@Au NP by using a thiol molecule with the chemical formula 61
(SH-PEG-NH2) as the linker to see whether the designed nano-DDS with folat could be 62
a candidate for in vitro SF delivery or not. Herein, we evaluated in vitro SF-delivery by 63
viability assay (MTT assay), fluorescence microscopy, and apoptosis assay (flow 64
cytometry) of the human breast cancer cells (MCF-7 line) in the presence of free SF, 65
FITC/FA@[Fe3O4@Au] NPs, SF-loaded FITC@[Fe3O4@Au] NPs, and SF-loaded 66
FITC/FA@[Fe3O4@Au] NPs. 67
Our results indicate that the achieved nano-DDS appears as a promising candidate 68
for in vitro study of SF delivery. 69
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Materials and Methods 70
Cell line, culture conditions, reagents and instruments 71
All used chemicals were of analytical grade and purchased from commercial sources. 72
4´,6´-diamidino-2-phenylindole (DAPI), FeCl2•4H2O, FeCl3•6H2O, HAuCl4•4H2O 99%, 73
d,l -sulforaphane, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 74
streptomycin, penicillin G, phosphate buffer (20 mM, pH=7.8) and corresponding salts 75
which were used throughout this research were obtained from Sigma-Aldrich or Merck. 76
Fetal bovine serum (FBS) and Dulbecco’s Modified Eagle’s Medium (DMEM) as a 77
culture medium and other supplements were obtained from Gibco (Germany). 78
MCF-7 cells were grown in DMEM medium supplemented with 10% (v/v) 79
heat-inactivated FBS, 2% l-glutamine, 2.7% sodium bicarbonate, 1% Hepes buffer, and 80
1% penicillin-streptomycin solution (GPS, Sigma) at 37 in humidified atmosphere 81
with 5% CO2. Cells were trypsinized in the solution of 0.05% trypsin and seeded into 82
96-well micro-plates at the density of 1×105 cells/well. MCF-7 (human breast 83
carcinoma) cell line was obtained from national cell bank of Iran (Pasteur institute, 84
Iran) and cultured in DMEM medium containing 2 mM L-glutamine and 10% FBS, 85
penicillin (50 IU/ml) and streptomycin (50 µg/ml). Cells were separated using 0.1% 86
trypsin and 10 µM EDTA in phosphate-buffered solution. 87
The powder XRD spectrum was recorded at room temperature (RT) with a Philips 88
X’pert 1710 diffractometer using Cu Kα (α = 1.54056 A). The morphologies of the 89
NPs were observed using SEM (Hitachi S-4800 II, Japan) equipped with energy 90
dispersive X-ray spectroscopy (EDX). The TEM analysis was performed on a Hitachi 91
H-7650 (Japan) operating at an acceleration voltage of 80 kv. The IR spectra were 92
taken using Nicolet FT-IR Magna 550 spectrographs applying spectroscopic grade KBr. 93
The size of NPs was assessed by DLS (Nano-ZS 90, Malvern Instrument, United 94
Kingdom). The temperature was kept at 25 during the measuring process and 95
measurements were recorded as the average of three test runs. The zeta potential of the 96
NPs was measured in folded capillary cells using Nano sizer (Zeta sizer Nano ZS90, 97
Malvern Instruments Ltd., Malvern, UK). 98
Synthesis of NH2-PEG-SH 99
Synthesis of α-tosyl-ω-hydroxyl PEG (I) To a solution of PEG (1450 g/mol, 100
3.45 mmol) in dry toluene, silver (I) oxide (5.2 mmol) and potassium iodide (0.7 mmol) 101
were added, then p-toluene sulfonyl chloride (3.5 mmol) was added in one portion [36]. 102
After 12 h stirring at RT, the mixture was filtered and the organic solvent evaporated. 103
The product was dissolved in 10 ml dichloromethane (CH2Cl2) and then precipitated by 104
drop-wise addition into diethyl ether (Et2O) and I was filtered.
1HNMR (DMSO): 7.79 105
(2H), 7.49 (2H), 4.56 (1H, OH), 4.11 (2H, CH2-OSO2), 3.49 (bs, PEG backbone), 2.43 106
(3H, s, CH3). 107
Synthesis of α-azide-ω-hydroxyl PEG (II) A mixture of I (3.0 mmol) and NaN3 108
(4 mmol) in 150 ml of dry DMF was stirred overnight at 90 under argon atmosphere. 109
The mixture was cooled down, filtered, and DMF was removed under vacuum. The 110
product was dissolved in CH2Cl2 and washed twice with brine and water. The organic 111
phase was dried over sodium sulfate and reduced to a small volume, and finally 112
precipitated by dropping into Et2O. Then II was filtered.
1H-NMR (DMSO): 4.56 (1H, 113
OH), 3.6 (2H, OCH2), 3.5 (bs, PEG backbone), 3.4 (2H, CH2-N3) [36]. 114
Synthesis of α-azide-ω-thioacetate PEG (III) To a mixture of II (3.0 mmol) in 115
100 ml CH2Cl2 were added NEt3 (10.0 mmol) and TsCl (10.0 mmol) and stirred 116
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overnight at RT. The solution was then filtered, and the filtrate was washed twice with 117
saturated NH4Cl solution and water. Next, the organic phase was dried over sodium 118
sulfate and filtered. The filtrate was concentrated by solvent evaporation, and then 119
added drop-wise into dry Et2O and the product (α-azide-ω-tosyl PEG) was collected by 120
filtration. Afterwards, freshly prepared sodium thioacetate (15.5 mmol) was added to a 121
solution of α-azide-ω-tosyl PEG (3 mmol) in 100 ml dry DMF under inert atmosphere, 122
and the mixture was stirred overnight at RT. After solvent evaporation, the residue was 123
dissolved in CH2Cl2 and treated with active charcoal for 2 h. The mixture was filtered, 124
and the filtrate was concentrated to small volume by rotary evaporation, and was added 125
into dry Et2O. Then III was filtered.
1H-NMR (CDCl3): 3.63 (bs, PEG backbone), 126
3.58 (2H, OCH2), 3.38 (2H, CH2-N3), 3.07 (2H, CH2-S), 2.32 (3H, s, COCH3) [36]. 127
Synthesis of HS-PEG-NH2 (IV) 128
PPh3 (10.0 mmol) was added to a solution of III (3.0 mmol) in 50 ml dry MeOH, and 129
the mixture was refluxed overnight under argon atmosphere. After cooling down the 130
solvent removed by rotary evaporation, the resulting solid was dissolved in 10 ml 131
CH2Cl2, and was added drop wise into dry Et2O and then IV was filtered.
1H-NMR 132
(CDCl3): 3.88 (2H, CH2-CH2-S), 3.64 (bs, PEG backbone), 3.15 (2H, CH2-NH2), 2.67 133
(2H, CH2-SH), 1.56 (1H, SH) [36]. 134
Synthesis of HS-PEG-NH-FA (V) 135
Folic acid (0.1 mmol) was added to a mixture of dicyclohexyl carbodiimide (DCC) 136
(0.15 mmol) and N-hydroxy succinimide (NHS) (0.12 mmol) in 3 ml of dry DMSO, the 137
mixture was left to stir at RT overnight in the dark. After the removal of the byproduct, 138
dicyclohexyl urea, the filtrate was mixed with IV (0.11 mmol) and stirred at RT for 139
24 h. Then V was precipitated by adding dry Et2O, dried in vacuum, and was stored at 140
-20. 1HNMR (CD3OD): δ=11.02 (1H,-COOH), 8.97 (1H, N=CH), 8.50-8.56 (m, 3H, 141
1NH2 and 1NH), 6.75-8.01 (m, 5H, 4CH and 1NH), 4.31-4.42 (m, 4H, 1CH2, 1CH, and 142
1NH), 3.78 (2H, CH2-CH2-SH), 3.58-3.64 (bs, PEG backbone), 3.20 (t, 2H, CH2-NH), 143
2.70 (t, 2H, CH2-SH), 2.05-2.10 (m, 4H, 2CH2), 1.56 (s, 1H, SH). 144
Synthesis of HS-PEG-FITC (VI) 145
FITC (10.0 µmol) and polymer IV (11.0 µmol) was dissolved in 2 ml EtOH and 2 ml 146
CHCl3 and stirred in the dark, under argon atmosphere. After 4 h, the product was 147
precipitated by adding Et2O and dried. Then VI was filtered and stored at -20. 148
1HNMR (CD3OD): δ= 11.09 (s, 1H, 1COOH), 6.31- 7.45 (m, 8H, 8CHAromatic), 6.18 149
(s, 1H, 1CHAromatic), 4.95 (bs, 1H, 1OH), 4.14 (bs, 1H, 1NH), 3.72 (t, 2H, 150
CH2-CH2-SH), 3.56-3.64 (m, PEG backbone), 2.73 (t, 2H, CH2-SH), 1.56 (s, 1H, SH). 151
Synthesis of Magnetic Nanocarrier 152
Synthesis of Fe3O4-Gold Core Shell Magnetic NPs FeCl2•4H2O (2 ml, 2M) 153
and FeCl3•6H2O (4 ml, 2M) were stirred at RT for 1 h, under argon atmosphere. Then, 154
a concentrated solution of NaOH was drop-wise added under the inert atmosphere and 155
the pH of the solution was carefully adjusted between 11 to 12. The solution was stirred 156
at 20 for 1 h and then heated to 90 for another 1 h. Afterwards the system was 157
kept at the same temperature for 1 h. Subsequently, Fe3O4 NPs were separated by 158
using an external magnetic field and washed with of deionized water (DW) to achieve a 159
neutral Fe3O4 suspension. Then the synthesis of [Fe3O4@Au] NPs was carried out 160
according to Cui et al. [37] with some modifications. As-synthesized Fe3O4 NPs were 161
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applied as seed for the preparation of Fe3O4 gold core shell NPs. First, Fe3O4 NPs were 162
dispersed in a micellar solution containing 0.1 M HAuCl4•4H2O solution, 3 g CTAB, 163
2.5 g 1-butanol and 15 g octane for 20 min using sonication, and then slowly mixed in a 164
shaking incubator at 38 to allow the adsorption of Au3+ into the Fe3O4 surface. 165
Then a solution of NaBH4 was added to the system as reducing agent and the mixture 166
was incubated at RT in a shaking incubator. The formed NPs were washed with DW 167
until neutralization. Finally, the resulting [Fe3O4@Au] NPs was filtered and dried under 168
vacuum. 169
Synthesis of FITC/FA@[Fe3O4@Au] NPs 40 mg of [Fe3O4@Au] in 5 ml of dry 170
CHCl3 was added to a suspension of 50 mg of V and 20 mg VI in CHCl3. The mixture 171
was stirred 2 h in the dark under argon atmosphere at RT. The particles were then 172
collected by applying an external magnetic device or centrifugation, and washed with 173
CHCl3 and hexane (1:5 V/V). To obtain pure FITC/FA@[Fe3O4@Au] NPs, the product 174
was dispersed in DW for dialysis for 24 h to remove unreacted organic molecules. 175
Chemical and Physical Stability of FITC/FA@[Fe3O4@Au] NPs 176
The chemical stability of the functionalized [Fe3O4@Au] NPs under physiological 177
conditions was carried out in DMEM media (pH=7.4). FITC/FA@[Fe3O4@Au] NPs 178
(5 mg/ml) was suspended in DMEM media at RT and placed inside the dialysis bag 179
with a molecular cut-off of 14 kDa and then placed into DMEM cell culture media. The 180
particles were stirred with sampling at 1, 2, 4, 6, 8, 12, 16 and 24 h. The samples were 181
analyzed for FITC content using fluorescence spectrometer (perkin Elmer) at 488 nm. 182
Increasing in FITC content outside the dialysis chamber indicates particle degradation. 183
Therefore, at each time point 100 µl of supernatant was picked up as a sample and then, 184
100 µl of fresh medium was added to remain the volume at the previous scale. The 185
absorbance of FITC was recorded, and the total release of FITC was calculated. To 186
study physical stability of the synthesized NPs against aggregation, the particle sizes of 187
FITC/FA@[Fe3O4@Au] NPs were assayed by DLS in PBS buffer. PBS represents the 188
typical pH of physiological medium and is a very common biological buffer. The average 189
hydrodynamic diameters of FITC/FA@[Fe3O4@Au] NPs was measured as a function of 190
time up to 5 days. 191
SF Loading and Releasing 192
FITC/FA@[Fe3O4@Au] NPs with the final concentration of 0.150 mg/ml was first 193
sonicated with SF with an initial concentration of 0.300 mg/ml for 30 min and then 194
stirred overnight at RT in the dark. The samples were separated applying an external 195
magnet device, and washed with dry EtOH. The SF concentration in the liquid layer 196
was measured using a standard SF concentration curve generated with an UV-visible 197
spectrophotometer at 235 nm from a series of SF solutions with different concentrations. 198
The drug loading efficiency (DLE) of FITC/FA@[Fe3O4@Au] NPs can be calculated by 199






where WIni, WRes, and WFITC/FA@[Fe3O4@Au] are the weight of initial drug for loading, the 201
weight of residual drug in solution after being loaded onto FITC/FA@[Fe3O4@Au] NPs, 202
and the weight of FITC/FA@[Fe3O4@Au] NPs for loading, respectively. The release 203
behavior of 5 mg of SF-loaded FITC/FA@[Fe3O4@Au] NPs in 5 ml of 204
phosphate-buffered solution (PBS) at 37 was studied using a dialysis bag. At the 205
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time points of experiments, 0.5 ml of solution was collected and stored at 4 until 206
detection. After each time of sampling, 0.5 ml of fresh PBS (pH=7.4) was replaced to 207
maintain the volume. Drug release was measured using the ultraviolet-visible 208
spectrophotometer at 235 nm. Measuring of the release of SF from SF-loaded 209
FITC/FA@[Fe3O4@Au] NPs was also repeated exactly in the case of citrate buffer 210
(pH=5.4). Meanwhile, the drug release were measured for the 211
FITC/FA@[Fe3O4@Au] NPs as the control. 212
Cell Viability by MTT Assay 213
To study the cytotoxicity of free SF, FITC/FA@[Fe3O4@Au] NPs, SF-loaded 214
FITC@[Fe3O4@Au] NPs, and SF-loaded FITC/FA@[Fe3O4@Au] NPs in MCF-7 cell 215
line; the colorimetric assay was applied to measure the reduction of MTT by 216
mitochondrial succinate dehydrogenase. The MTT assay was performed at 24, 48, and 217
72 h of treatments. Cells were seeded into 96-well plates (104 cells/well). After 24 h, 218
diverse concentrations (range of 0.04-24 µmol/l in DMEM) of free SF, 219
FITC/FA@[Fe3O4@Au] NPs, SF-loaded FITC@[Fe3O4@Au] NPs, and SF-loaded 220
FITC/FA@[Fe3O4@Au] NPs were applied. Then, after 24, 48, and 72 h of the 221
treatment, the medium was removed and the cells were washed twice with PBS, and 222
afterwards 20 µl of MTT (5 mg/ml) was added to each well. Plates were incubated for 223
3 h at 37. Then, 100 µl of DMSO was added to each well and left at 37 for 15 min. 224
The optical density was measured at 570 nm using a micro-plate reader (Biotek, USA). 225
The experiment of cytotoxicity of SF-loaded FITC/FA@[Fe3O4@Au] NPs in MCF-7 cell 226
line after 24, 48, and 72 h of treatments were performed with six repeats, but the rest of 227
the experiments with free SF, FITC/FA@[Fe3O4@Au], and SF-loaded 228
FITC@[Fe3O4@Au] were performed in triplicate. 229
Cellular Uptake by Fluorescence Microscopy 230
Cells were seeded into 6 well plates (105 cells/well) and allowed to adhere. MCF-7 cells 231
were considered as target. The cells were incubated at 37 at predetermined time 232
points with free SF, FITC@[Fe3O4@Au] NPs, SF-loaded FITC@[Fe3O4@Au] NPs, and 233
SF-loaded FITC/FA@[Fe3O4@Au] NPs with the final concentration of 3.5 µmol/l. The 234
cells were washed twice with PBS, before the digital-camera-microscopy. Observation 235
was done under an inverted microscope (Olympus, IX81). The U-MWIB3 (BP-460-495 236
nm) filter was used to perform fluorescence microscopy. The digital images were 237
captured with a DP72 digital camera. In order to indicate the intensity of FITC in the 238
fluorescence images, images were analyzed using Matlab (The Math Works, Natick, 239
MA). A colorbar was utilized to represent different intensity values. 240
Cell Apoptosis by Flow Cytometry 241
Apoptosis of MCF-7 cells was studied by flow cytometry using Annexin-V/PI staining 242
because phosphatidyl serine is unprotected and detectable by Annexin-V at the external 243
surface of the cells at initial stages of apoptosis. Briefly, cells were seeded into 6 well 244
plates (105 cells/well) and were treated for 48 h with free SF, 245
FITC/FA@[Fe3O4@Au] NPs, and SF-loaded FITC/FA@[Fe3O4@Au] NPs at IC50 246
concentration (24 µmol/l). After incubation, the cells were washed twice with cold PBS 247
and then re-suspended in 1× binding buffer (10 mM Hepes, 140 mM NaCl, and 2.5 mM 248
CaCl2, pH=7.2). 100 µl of the solution transferred to 5 ml culture tube, and 5 µl of 249
Annexin V-FITC, and 5 µl PI were added and incubated in dark situation for 15 min at 250
RT. Then, 400 µl of 1× binding buffer was added to each tube and analyzed by Flow 251
Cytometry (Becton Dickinson FACS Canto II) within 1 h. 252
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Gene Expression Profile by Real-Time PCR 253
Total RNA of MCF-7 cells (105 cells/ml) which were treated with 24 µmol/l of free SF, 254
FITC/FA@[Fe3O4@Au] NPs, SF-loaded FITC@[Fe3O4@Au] NPs, and SF-loaded 255
FITC/FA@[Fe3O4@Au] NPs (72 h) was extracted by using TRIzol reagent according to 256
the manufacturer’s instructions (Invitrogen Life Technologies). Total mRNA was 257
directly processed to cDNA by reverse transcription with cDNA synthesis Kit 258
(Fermentas) in a 25 µl total volume reaction. The levels of mRNA of Bcl-2, Bcl-xL, Bak 259
and Bax mRNA were quantified by the Real Time PCR while endogenous gene GAPDH 260
were used as a control. Primers were designed using software primer express (Bcl-2 261
Forward: 5´-CAGGTTGAGGTTGTCCACAG-3´, Reverse: 262
5´-TGCTTATTCCAGAGCTCCCT-3´, Bcl-xL Forward: 263
5´-AACTGTGGTTCAGTGTGGGA-3´, Reverse: 5´-CTAGCTTCCTCCAAGATGGC-3´, 264
Bax Forward: 5´-GGGCAGTGTGATTTAGCAGA-3´, Reverse: 265
5´-TGAACCAAGATCATGCCATT-3´, Bak Forward: 266
5´-GGAAAGTTGCCCTGAGAAAG-3´, Reverse: 5´-TACTCAACACGCATGCAAGA-3´, 267
GAPDH Forward: 5´-ATCATCCCTGCCTCTACTGG-3´, Reverse: 268
5´-GTCAGGTCCACCACTGACAC-3´). The thermal cycling conditions were as follows: 269
initial denaturation at 95 for 10 min, followed by 45 cycles of 94 for 15 s, and 270
60 for 60 s. This program was followed by a melting curve program (60-98 with a 271
heating rate of 0.3 /s and continuous fluorescence measurement). 272
Statistical Analysis 273
Matlab was used for all statistical analysis. Data are expressed as mean ± SEM. 274
Statistical analysis to detect differences between groups was done by using one-way 275
analysis of variance (ANOVA) with p-value <0.05 to indicate statistically significant 276
differences. Post-hoc pairwise comparisons of Tukey(-Kramer) and Bonferroni tests were 277
preformed and the smaller of the two intervals was taken. 278
Results 279
Preparation and Characterization of Nanocarrier 280
The gold coated Fe3O4 NPs including [Fe3O4@Au], FITC/FA@[Fe3O4@Au] NPs, and 281
SF-loaded FITC/FA@[Fe3O4@Au] NPs were prepared as shown in Fig. 1A. 282
[Fe3O4@Au] NPs were synthesized via co-precipitation of ferrous (Fe
2+) and ferric 283
(Fe3+) ions followed by coating resulting Fe3O4@ NPs with gold NPs. The surface of 284
[Fe3O4@Au] NPs was decorated with thiolated polyethylene glycol-folic acid 285
(HS-PEG-FA) and thiolated polyethylene glycol-Fluorescein isothiocyanate 286
(HS-PEG-FITC) in order to fabricate FITC/FA@[Fe3O4@Au] NPs as an eligible 287
magnetic nanocarrier. Due to the large affinity of thiol (S-H) function to the gold NPs, 288
the thiolated PEG linkers are assembled around the [Fe3O4@Au] NPs through the 289
self-assembly to achieve FITC/FA@[Fe3O4@Au] NPs. 290
Figure 1. Schematic procedure of SF-loaded FITC/FA@[Fe3O4@Au] NPs
synthesis (A), and TEM and SEM of NPs (B,C). A: Schematic procedure for
synthesizing SF-loaded FITC/FA@[Fe3O4@Au] NPs. Abbreviations: PEG,
poly(ethylene glycol); FA, folate; FITC, fluorescence isothiocyanate; SF, sulforaphane;
NPs, nanoparticles. B: TEM of FITC/FA@[Fe3O4@Au] NPs. C: SEM of
FITC/FA@[Fe3O4@Au] NPs.
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TEM and SEM were applied to recognize the structural order and morphology of 291
FITC/FA@[Fe3O4@Au] NPs (see Figs. 1B and 1C). The analysis of SEM and TEM 292
images showed that the average size of the synthesized NPs is less than 40 nm. The 293
particle size distribution function confirmed that the size of NPs was 37± 2.1 nm, which 294
indicates a small heterogeneity in the size of the particles. 295
Energy dispersive X-ray (EDX) spectroscopy was done to investigate the presence of 296
Au and Fe in the NPs. EDX spectrum of the NPs is presented in Fig. 2, which confirms 297
the existence of Au and Fe in the [Fe3O4@Au] NPs. 298
Figure 2. EDX and FTIR spectrum of NPs. The energy dispersive X-ray
spectrum of [Fe3O4@Au] NPs. Inset: The FT-IR spectra of free SF,
FITC/FA@[Fe3O4@Au] NPs, and SF-loaded FITC/FA@[Fe3O4@Au] NPs.
To confirm the existence of iron oxide-gold core shell, the powder X-Ray diffraction 299
(XRD) experiment was used as an applicable technique. There were three bands in the 300
XRD pattern which attributable to the corresponding reflections of the solid gold at 301
2θ = 44.67◦, 51.72◦, and 76.71◦ (JCPDS#89-3697). But, the characteristic bands of 302
magnetic core no longer appeared in the XRD spectrum. The absence is due to the fact 303
that all iron oxide NPs are coated with 2 nm thickness of gold [25,38]. 304
In order to confirm the successful loading of SF onto the 305
FITC/FA@[Fe3O4@Au] NPs, Fourier transform infrared spectroscopy (FTIR) of free SF, 306
FITC/FA@[Fe3O4@Au] NPs, and SF-loaded FITC/FA@[Fe3O4@Au] NPs was done 307
(inset of Fig. 2). In the spectrum of SF-loaded FITC/FA@[Fe3O4@Au] NPs, there are 308
two strong absorbance picks at 2182 and 2109 cm−1. These absorbance picks are 309
belonged to the stretching vibration of -N=C=S. Besides that, two other absorption 310
peaks at 1452 and 1350 cm−1 are belonged to the deformation vibration of CH3. 311
The thermal gravimetric analysis (TGA) of FITC/FA@[Fe3O4@Au] NPs showed the 312
first peak at 95 and the second peak at 395 which correspond to desorption of 313
water and loss of the organic spacer group, respectively. Therefore, the loading of 314
FITC/FA was about 20%. Following that, the TGA analysis of SF-loaded 315
FITC/FA@[Fe3O4@Au] NPs showed the weight loss about 70%, which is attributed to 316
removing SF and FITC/FA groups. Hence, in average 2.8 mmol/g of SF was loaded 317
onto the surface of NPs. 318
Since the existence of the magnetic NP in the designed NP would be a good 319
candidate for in vivo therapy in animal model (using MRI), then it is important to 320
synthesize the magnetic-core-shell with sufficient superparamagnetic property. To 321
investigate it, the magnetic (M) hysteresis loop of the same mass of the [Fe3O4@Au] 322
and FITC/FA@[Fe3O4@Au] NPs were investigated while magnetic field (H) at RT was 323
applied. As shown in Fig. 3, the value of magnetic saturation (Ms) of the [Fe3O4@Au] 324
and FITC/FA@[Fe3O4@Au] NPs were 7.24 and 2.07 emu/g at RT, respectively. The 325
lower magnetic saturation of later NPs could be due to the influence of the PEG group. 326
Furthermore, the hysteresis loop for the samples were completely reversible. The 327
reversibility in hysteresis loop confirms that no aggregation imposes to the NPs in the 328
external magnetic field and the NPs exhibit superparamagnetic property.
Figure 3. Magnetization hysteresis loop of NPs. The room-temperature
magnetization (M) hysteresis loop curves of the same mass of [Fe3O4@Au] NPs and
FITC/FA@[Fe3O4@Au] NPs as a function of applied magnetic field (H).
329
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Particle Size Distribution and Zeta Potential Measurement 330
The NPs with average diameter less than 100 nm are suitable to pass through cell 331
membrane and works well for drug delivery. The mean diameter of the synthesized 332
FITC/FA@[Fe3O4@Au] NPs and SF-loaded FITC/FA@[Fe3O4@Au] NPs were 333
measured by dynamic light-scattering (DLS) technique. The mean size of the 334
synthesized FITC/FA@[Fe3O4@Au] NPs and SF-loaded FITC/FA@[Fe3O4@Au] NPs 335
were obtained 31.42±1.2 nm and 34.59±0.8 nm, respectively. The average size of both 336
are less than 50 nm. Based on our measurement, NPs with and without drug are almost 337
with small standard deviation in size (narrow particle size distribution function). 338
Another physical quantity which affects on cellular up take is the surface charge of 339
synthesized NPs. The NPs with positive charge (size smaller than 100 nm) cross the cell 340
membrane and readily taken up by cells [39]. The zeta potential of SF-loaded 341
FITC/FA@[Fe3O4@Au] NP was measured and 9.47±4.6 mv was obtained which is 342
suitable for cell membrane penetration. 343
Chemical and Physical Stability of FITC/FA@[Fe3O4@Au] NPs 344
To investigate the chemical stability of FITC/FA@[Fe3O4@Au] NPs, release of FITC 345
from NPs was studied by UV-visible spectroscopy at 488 nm. The release of FITC could 346
occurred due to the ligand exchange in the presence of a reductive media. The release 347
profile was measured in two mediums including DMEM (Fig. 4A) and glutathione 348
(GSH). The releasing rate of FITC from FITC/FA@[Fe3O4@Au] during 24 h in DMEM 349
shows a two-steps pattern. An initial burst release at the first 8 h which is followed by a 350
relatively slower release during the next 16 h. At the first 8 h, the FITC-release was 351
reached to around 17%, thereafter it remained almost steady through the next 16 h. At 352
24 h, the amount of FITC-release was about 18.87% in the cell culture medium 353
(pH=7.4). This implies that FITC/FA@[Fe3O4@Au] NPs which are suitable as drug 354
carriers will reach to the cells with minimum lose of FITC (at 24 h). 355
The release of FITC moiety from the NPs in 5% GSH at 24 h showed no significant 356
change in compare to DMEM. To the best of our knowledge, the disulfide bonds are 357
cleaved by reducing agents such as GSH. Our synthesized NPs contains FITC moiety 358
without any linkage S-S bond. Therefore, it is clear why there was not observed a 359
significant change in the release profile of FITC from FITC/FA@[Fe3O4@Au] NPs. 360
To elaborate on the physical stability of FITC/FA@[Fe3O4@Au] NPs, the change in 361
size of the NPs was studied. Change in size may occur during in vitro experiment. 362
Therefore, the physical stability of the FITC/FA@[Fe3O4@Au] NPs at physiological pH 363
was measured during 120 h. As the graph shows (see Fig. 4B), the average diameter of 364
FITC/FA@[Fe3O4@Au] NPs did not considerably change during 120 h in comparison 365
with [Fe3O4@Au] NPs. Hence, from physical point of view the designed NPs were 366
relatively stable.
Figure 4. Release of FITC from NPs (A) and average hydrodynamic (B) of
NPs. A: Release of FITC from FITC/FA@[Fe3O4@Au] NPs. B: The average
hydrodynamic diameter of [Fe3O4@Au] and FITC/FA@[Fe3O4@Au] NPs at pH=7.4.
367
Drug Loading and Releasing 368
SF was confined in the organic PEG network around [Fe3O4@Au] NPs. As Fig. 5A 369
shows, the amount of SF-loaded onto the FITC/FA@[Fe3O4@Au] NPs could be reached 370
up to 56% after 24 h. 371
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Besides the SF loading, the release profile of SF from the surface of SF-loaded 372
FITC/FA@[Fe3O4@Au] NPs was evaluated in two mediums including PBS and citrate 373
buffer (Fig. 5B). As it is shown in Fig. 5B, at the same time (and longer than 72 h) of 374
incubation SF-loaded FITC/FA@[Fe3O4@Au] NPs with MCF-7 cells, the release of SF 375
form the NP at the pH of 5.4 (citrate buffer), about twenty percent is more than the 376
release of SF form the NP at the pH of 7.4 (PBS).
Figure 5. SF loading (A) and releasing (B). A: The profile of SF loading in
FITC/FA@[Fe3O4@Au] NPs. B: The profile of SF releasing from SF-loaded




To study the cytotoxicity of SF-loaded FITC/FA@[Fe3O4@Au] NPs, MCF-7 cells were 379
incubated with different concentrations of SF-loaded FITC/FA@[Fe3O4@Au] NPs and 380
the percentage of live cells after 24, 48, and 72 h of treatments were measured (Fig. 6A). 381
There is a significant (p-value <0.05) decrease in the percentage of cell viability at the 382
concentrations of 1.5, 3 and 6 µmol/l at 48 h versus 24 h. Also, there is a significant 383
decrease (p-value <0.05) in the percentage of cell viability at the concentrations of 0.75, 384
1.5, 3, 6, 12 and 24 µmol/l after 72 h versus 24 h. Finally, statistical analysis with the 385
same p-value reveals that there is a significant decrease in the percentage of cell viability 386
at the concentrations of 1.5 and 3 µmol/l after 72 h versus 48 h. Furthermore, at any 387
time, there is no significant decrease in the percentage of cell viability at concentrations 388
less than 0.37 µmol/l. Therefore, at concentrations lower than 1.5 µmol/l, the effect of 389
SF-loaded FITC/FA@[Fe3O4@Au] NPs is not considerable. Besides that, at the 390
concentrations more than 6 µmol/l of SF-loaded FITC/FA@[Fe3O4@Au] NPs, the cell 391
viability did not change by time. Hence, it seems that the most effective concentration 392
of SF-loaded FITC/FA@[Fe3O4@Au] NPs on cell viability is between 1.5 to 6 µmol/l. 393
Figure 6. Viability of cells at different conditions. Viability of MCF-7 cells
which were assessed A: after 24 h, 48 h, and 72 h of incubation with different
concentrations of SF-loaded FITC/FA@[Fe3O4@Au] NPs. B: at different concentrations
of incubation with free SF, FITC/FA@[Fe3O4@Au] NPs, SF-loaded
FITC@[Fe3O4@Au] NPs, and SF-loaded FITC/FA@[Fe3O4@Au] NPs. Data are
presented as the mean ± standard deviation of replicates.
To verify the usefulness of the designed NPs as a potential drug carrier, at the 394
concentration of SF-loaded FITC/FA@[Fe3O4@Au] NPs, which its efficiency on the cell 395
viability was obtained before, the cytotoxicity of free SF, FITC/FA@[Fe3O4@Au] NPs, 396
and SF-loaded FITC@[Fe3O4@Au] NPs were studied with the same procedure. As 397
Fig. 6B shows, at concentrations more than 12 µmol/l, the SF can induce more cell 398
death but inducing cell death with a high concentration of a drug (which is an unstable 399
drug in our case) is not the aim of drug delivery system. The cytotoxicity of SF-loaded 400
FITC/@[Fe3O4@Au] NPs significantly (p-value < 0.01) increases at the concentrations 401
of 1.5, 3 and 6 µmol/l versus FITC/FA@[Fe3O4@Au] NPs. Finally, the cytotoxicity of 402
SF-loaded FITC/FA@[Fe3O4@Au] NPs becomes drastically significant (p-value <0.001) 403
at concentrations of 1.5 and 3 µmol/l. Both of the concentrations are in the rage of 404
effective concentration of SF-loaded FITC/FA@[Fe3O4@Au] NPs which we obtained 405
before (Fig. 6A). To sum up, according to the cytotoxicity study using MTT assay, the 406
FITC/FA@[Fe3O4@Au] NPs has a good effect as a vehicle for SF delivery at 407
concentrations of 1.5 and 3 µmol/l. 408
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Cellular Uptake 409
In order to investigate the cellular uptake, images of control cells (Figs. 7A-C), 410
incubated cells with free SF (Figs. 7D-F), and incubated cells with 411
FITC/FA@[Fe3O4@Au] NPs (Figs. 7G-I) were prepared. The emerged images of DAPI 412
with bright field images (Figs. 7B and 7E), and FITC-channel (Fig. 7I) were prepared. 413
Figure 7. Optical microscopy images of cells after 24 h. A: Bright-field image,
B: Fluorescence image of DAPI detection, and C: Combined of A and B, after 24 h
incubation of MCF-7 cells (control). D: Bright-field image, E: Fluorescence image of
DAPI detection, and F: Combined of D and E, after 24 h incubation of MCF-7 cells
with free SF. G: bright-field image, H: fluorescence image of DAPI detection, and I:
fluorescence image of FITC detection of the same area after 24 h incubation of MCF-7
cells with FITC@[Fe3O4@Au] NPs.
Cellular uptake of SF-loaded FITC/FA@[Fe3O4@Au] NPs and SF-Loaded 414
FITC@[Fe3O4@Au] NPs after 24 h incubation were investigated and detected by 415
recording the bright-field image (Figs. 8A and 8D), fluorescence image of FITC 416
detection (Figs. 8B and 8E), and emerged images of FITC with bright field images 417
(Figs. 8C and 8F), respectively. According to the Figs. 8B and 8E, with the same 418
concentration of SF-loaded FITC/FA@[Fe3O4@Au] NPs and SF-loaded 419
FITC@[Fe3O4@Au] NPs, two properties of 1) homogenous (relatively) FITC-emission in 420
the background, and 2) lower ratio (relatively) of the background-FITC-emission to the 421
intercellular-FITC-emission indicate that the presence of the folate in 422
FITC@[Fe3O4@Au] NPs, does not lead to a decrease in SF delivery and both proposed 423
NPs deliver SF. 424
Figure 8. Optical microscopy images of incubated cells by SF-loaded
FITC@[Fe3O4@Au] NPs and SF-loaded FITC/FA@[Fe3O4@Au] NPs after
24 h. A: Bright-field image, B: Fluorescence image of FITC detection, and C:
Combined of A and B, after 24 h incubation of MCF-7 cells with SF-loaded
FITC@/FA[Fe3O4@Au] NPs. D: Bright-field image, E: Fluorescence image of FITC
detection, and F: Combined of D and E, after 24 h incubation of MCF-7 cells with
SF-loaded FITC@[Fe3O4@Au] NPs.
The same method of microscopy was used for 72 h incubation of SF-loaded 425
FITC/FA@[Fe3O4@Au] NPs with MCF-7 cells. As is shown in Figs. 9A-L, there is a 426
one-to-one correspondence between live cells (DAPI staining) and nanoparticle/drug 427
uptake by MCF-7 cells. Hence, the FITC/FA@[Fe3O4@Au] NPs were up taken by all 428
(all in the field of view of the image) MCF-7 cells at 24 h of incubation (Figs. 9A-F). 429
Based on the same colorbar corresponding the fluorescence intensity of FITC-emission, 430
after 72 h, cells uptake more SF-loaded FITC/FA@[Fe3O4@Au] NPs. From the images 431
it is possible to evaluate whether the drug release occurs intracellularly following NPs 432
uptake or the drug release occurs extracellularly prior to NPs uptake/delivery. The 433
dynamics of the drug release at two different pH were studied to estimate the 434
percentage of releasing at different environmental conditions. Since the pH of the release 435
medium is merely close to the pH of PBS at 24 h of incubation with SF-loaded 436
FITC/FA@[Fe3O4@Au] NPs, about 30% of SF is released from SF-loaded 437
FITC/FA@[Fe3O4@Au] NPs, extracellularly. It seems, probably during 24 h of 438
incubation SF-loaded FITC/FA@[Fe3O4@Au] NPs with cells, the rest of the loaded 439
drug (about 70%) enter via NPs, and release inside the cell. 440
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Figure 9. Optical microscopy images of incubated cells by SF-loaded
FITC/FA@[Fe3O4@Au] NPs after 24 and 72 h. A: bright-field image, B:
fluorescence image of FITC detection, and C: fluorescence image of DAPI detection of
the same area after 24 h incubation of MCF-7 cells with SF-loaded
FITC/FA@[Fe3O4@Au] NPs. D: The corresponding fluorescence intensity maps
(colorbar shown) of FITC (in SF-loaded FITC/FA@[Fe3O4@Au] NPs) distribution of
Fig. 9B. E: Combined of A and B. F: Combined of A and C. G: bright-field image, H:
fluorescence image of FITC detection, and I: fluorescence image of DAPI detection of
the same area after 72 h incubation of MCF-7 cells with SF-loaded
FITC/FA@[Fe3O4@Au] NPs. J: The corresponding fluorescence intensity maps
(colorbar shown) of FITC (in SF-loaded FITC/FA@[Fe3O4@Au] NPs) distribution of
Fig. 9B. K: Combined of G and H. L: Combined of G and I.
Cell Apoptosis 441
A double staining flow cytometric assay using Annexin V/FITC (A), which reacts with 442
viable cells, and propidium iodide (PI) was performed to quantify the apoptotic MCF-7 443
cells accurately. Fig. 10A shows the percentages of MCF-7 cells viability (A−/PI−), 444
early apoptosis (A+/PI−), late apoptosis (A+/PI+) and necrosis (A−/PI+) after 445
treatment with free SF, FITC/FA@[Fe3O4@Au] NPs, SF-loaded 446
FITC@[Fe3O4@Au] NPs and SF-loaded FITC/FA@[Fe3O4@Au] NPs. Statistic analysis 447
of flow cytometric assay showed (Fig. 10B) that the percentage of live cells (A−/PI−) 448
were decreased significantly (P<0.0001) after treatment with free SF and SF-loaded 449
FITC/FA@[Fe3O4@Au] NPs in compare to the untreated cells (control group), while 450
the percentage of the treated cells with FITC/FA@[Fe3O4@Au] NPs, did not change 451
significantly. Also, the percentages of total apoptosis (early + late apoptosis) in cells 452
which were treated with free SF and SF- FITC/FA@[Fe3O4@Au] NPs increased 453
significantly (P<0.0001) in comparison with control. 454
Figure 10. Flow cytometric analysis (A and B) and the rate of gene
expression in MCF-7 cells (C). A: Flow cytometric analysis of MCF-7 cells were
treated with free SF, FITC/FA@[Fe3O4@Au] NPs, SF-loaded FITC@[Fe3O4@Au] NPs,
and SF-loaded FITC/FA@[Fe3O4@Au] NPs at equivalent SF concentration after 48 h.
B: SF-loaded FITC/FA@[Fe3O4@Au] NPs induces significantly apoptosis versus free SF.
Data are presented as the mean ± standard deviation of replicates. C: The rate of gene
expression in MCF-7 cells after 72 h treatment with free SF,
FITC/FA@[Fe3O4@Au] NPs, SF-loaded FITC@[Fe3O4@Au] NPs, and SF-loaded
FITC/FA@[Fe3O4@Au] NPs.
Gene Expression Profile 455
Effects of SF-loaded FITC/FA@[Fe3O4@Au] NPs on the mRNA expression of selected 456
genes was analyzed by Real-Time PCR. Statistical analysis of results (Fig. 10C) 457
indicate that after 72 h treatment with SF-loaded FITC/FA@[Fe3O4@Au] NPs, the 458
expression rates of bcl-2 and bcl-xL (anti-apoptotic) genes significantly (P<0.05) were 459
decreased while rates of mRNA expression of bax and bak (pro-apoptotic) (P<0.05) in 460
comparison with control group. 461
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Discussion and Conclusions 462
We have designed, synthesized and characterized a novel and robust nano-magnetic gold 463
DDS to improve the efficiency of SF delivery. The synthesized nano-magnetic vehicle 464
was characterized by a number of techniques such as EDX, XRD, VSM, FT-IR, TGA, 465
DLS, TEM, and SEM. 466
Owing to the hydrophilicity behavior of PEG function as surface modifier, the 467
aforementioned surface manipulations provide the convenient surface to encompass SF 468
via the electrostatic interaction between the S=O bond from SF and the oxygen groups 469
from hydrophilic PEG linker. Hence, in order to 1) overcome the SF-instability, 2) 470
improve SF-delivery, and 3) control SF-release, the surface of NPs was manipulated 471
with functionalized PEG. 472
In vitro cytotoxicity study (MTT assay) of MCF- cells showed that SF-loaded 473
FITC/FA@[Fe3O4@Au] NPs are more cytotoxic than free SF. The mechanism of 474
induced appotosis in MCF-7 cells was revealed by double staining flow cytometric assay. 475
Based on the statistical analysis of the obtained data, the rates of total apoptosis 476
significantly were increased after loading onto the synthesized nano-magnetic vehicles in 477
comparison with free SF. Following detection of apoptosis mechanism in cytotoxicity of 478
SF-loaded FITC/FA@[Fe3O4@Au] NPs for MCF-7 cells, the expression rate of 479
anti-apoptotic genes (bcl-2 and bcl-xL) and pro-apoptotic genes (bax and bak) were 480
quantified by Real-Time PCR technique. The expression rate of bcl-2 and bcl-xL genes 481
significantly were decreased in comparison with untreated cells. 482
Notably, in vitro breast cancer study showed that FITC/FA@[Fe3O4@Au] NP would
be a proper candidate nanocarrier for SF-delivery and provides a suitable and
appropriate system for pH-dependent delivery of SF. These results would open new
horizons to develop promising nano-DDSs to design further nanoparticle systems to
improve the therapeutic effect of SF in the future.
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